Business
GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection
Patent Supports MultiAntigenic VLP-MVA Vaccine Design for Products Used Against Endemic and Emerging Infectious Diseases ATLANTA, GA - June 25, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq:GOVX), a biotechnology company developing multi-antigen va...
About this update from Geovax Labs, Inc.
[{"type":"image","caption":"","headline":"GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Patent Supports MultiAntigenic VLP-MVA Vaccine Design for Products Used Against Endemic and Emerging Infectious Diseases","length":120,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - June 25, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq:GOVX), a biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and cancers, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,329,808, from patent application No.18,394,580, titled "Compositions and Methods for Generating an Immune Response to Treat or Prevent Malaria."","length":439,"tagName":"p"},{"type":"text","content":"The patent covers compositions comprising GeoVax's recombinant Modified Vaccinia Ankara (MVA) viral vector expressing immunogenic proteins from Plasmodium falciparum (the causative agent of malaria). The novel construct supports expression of virus-like particles (VLPs) assembled from P. falciparum circumsporozoite protein (CSP) or gametocyte surface protein Pfs230 fused to a Marburg virus glycoprotein transmembrane domain, together with the Marburg VP40 matrix protein. The expressed proteins are assembled in vivo as VLPs, which is an antigen presentation design used to enhance vaccine potency and induce both humoral and T-cell responses.","length":650,"tagName":"p"},{"type":"text","content":"David Dodd, GeoVax President and CEO, commented, "This new patent further demonstrates our commitment to advancing critically important vaccines that address both globally persistent and emerging high-consequence pathogens. The vaccine construct exemplifies our multi-antigenic platform strategy that is critical to pandemic preparedness and global health security. While our clinical-stage programs remain our immediate focus, protecting our innovation pipeline through issued pat...